Details for Patent: 11,331,292
✉ Email this page to a colleague
Which drugs does patent 11,331,292 protect, and when does it expire?
Patent 11,331,292 protects IQIRVO and is included in one NDA.
This patent has forty-six patent family members in thirty-one countries.
Summary for Patent: 11,331,292
| Title: | Methods of treatment of cholestatic diseases |
| Abstract: | The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC. |
| Inventor(s): | Remy HANF |
| Assignee: | Genfit SA |
| Application Number: | US16/894,110 |
|
Patent Claim Types: see list of patent claims | Use; |
| Patent landscape, scope, and claims: |
More… ↓ |
Recent additions to Drugs Protected by US Patent 11,331,292
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ipsen | IQIRVO | elafibranor | TABLET | 218860 | Jun 10, 2024 | RX | Yes | 11,331,292 | ⤷ Start Trial | U-1854 | TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 11,331,292
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ipsen | IQIRVO | elafibranor | TABLET;ORAL | 218860-001 | Jun 10, 2024 | RX | Yes | Yes | 11,331,292 | ⤷ Start Trial | TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,331,292
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3435996 | ⤷ Start Trial | 301342 | Netherlands | ⤷ Start Trial |
| European Patent Office | 3435996 | ⤷ Start Trial | C20250032 | Finland | ⤷ Start Trial |
| European Patent Office | 3435996 | ⤷ Start Trial | CA 2025 00035 | Denmark | ⤷ Start Trial |
| European Patent Office | 3435996 | ⤷ Start Trial | PA2025535 | Lithuania | ⤷ Start Trial |
| European Patent Office | 3435996 | ⤷ Start Trial | LUC50022 | Luxembourg | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
